CPH 0.00% 0.9¢ creso pharma limited

Ann: Trading Halt, page-25

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,651 Posts.
    lightbulb Created with Sketch. 2257
    I haven't been watching CPH as closely and actually didn't even notice this, but thanks to thegekko for having a dishonest attack on me (clearly in an attempt at revenge for my CPH) in another company's discussion I figured something was probably stirring over here, haha.

    This shake of the tin won't come as any surprise to anyone with any understanding of business or familiarity with CPH. It's funny though honestly a bit sad that holders often don't see it coming. CPH's entire business model is to pump with flowery but substance-lacking announcements which are highly misleading, pretend the business is potentially viable in order to excite investors, then raise capital like this, which is the true source of their income, and most of it goes to their own wages, 'staff costs', 'consultancy fees' etc.

    Many of us point out at every cycle that funds are low and a CR will be needed soon, and yet each time it somehow catches people off guard (there's some correlation between those people and those who proudly brag about having put the bears on ignore... bless their cotton socks).

    6.9c is a pretty high figure for this CR, but as I've said for years, raising capital is what CPH does best. We shouldn't have to wait long to see the SP below 6.9c

    You almost have to admire them for being able to continue along like this even in the midst of a criminal investigation. Their strategies have worked well for years but some heads will roll in due course.
 
watchlist Created with Sketch. Add CPH (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.